Posted by Michael Wonder on 24 Feb 2019
Shionogi receives European Union Marketing Authorisation for lusutrombopag for the treatment of severe thrombocytopenia in adults with chronic liver disease undergoing invasive procedures
22 February 2019 - The approval of lusutrombopag is based on two pivotal Phase 3 randomised clinical trials, L-PLUS1 and L-PLUS2.
Shionogi announced today that the European Commission (EC) has granted marketing authorisation for lusutrombopag for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing an invasive procedure.
This decision by the EC has followed the positive opinion of the CHMP of the EMA in December 2018.
